Literature DB >> 145441

Combination drug therapy in treatment of Paget's disease of bone: clinical and metabolic response.

A G Hadjipavlou, G M Tsoukas, T N Siller, S Danais, F Greenwood.   

Abstract

Twenty-seven patients with symptomatic Paget's disease of bone were randomly treated with mithramycin, glucagon, and calcitonin given either alone or in combination. Mithramycin, at a dose of fifteen micrograms per kilogram of body weight per day, proved to be a relatively safe drug and elicited a rapid response with only transient side effects. Calcitonin combined with mithramycin was the most effective therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 145441

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  7 in total

1.  Medical staff conference. Paget disease of bone.

Authors: 
Journal:  West J Med       Date:  1978-09

Review 2.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Comparison between visual assessment and quantitative measurement of radioactivity on the bone scintigram in Paget's disease of bone.

Authors:  C J Vellenga; E K Pauwels; O L Bijvoet
Journal:  Eur J Nucl Med       Date:  1984

Review 4.  Principles of management of osteometabolic disorders affecting the aging spine.

Authors:  Alexander G Hadjipavlou; Paul G Katonis; Michael N Tzermiadianos; George M Tsoukas; George Sapkas
Journal:  Eur Spine J       Date:  2003-09-23       Impact factor: 3.134

5.  Paget's disease of bone. An update on management.

Authors:  D J Hosking
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

6.  Spinal cord compression in Paget's disease of bone treated medically.

Authors:  A S Jawad; H Berry
Journal:  J R Soc Med       Date:  1987-05       Impact factor: 18.000

Review 7.  The spine in Paget's disease.

Authors:  C Dell'Atti; V N Cassar-Pullicino; R K Lalam; B J Tins; P N M Tyrrell
Journal:  Skeletal Radiol       Date:  2007-04-05       Impact factor: 2.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.